Lupin launches authorised generic version of Apriso
Mesalamine Extended-Release Capsules 0.375 g (the authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older
Pharma major Lupin announced the launch of authorized generic version of Bausch Health’s Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S.
Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
Mesalamine Extended-Release Capsules 0.375 g. Apriso had an annual sales of approximately USD 290 million in the US (IQVIA MAT March 2020).
- Advertisement -